Maria Passhak1, Shlomit Strulov Shachar2, Amos Ofer3, Alexander Beny2. 1. Division of Oncology, Rambam Health Care Campus, POB 9602, 31096, Haifa, Israel. m_passhak@rambam.health.gov.il. 2. Division of Oncology, Rambam Health Care Campus, POB 9602, 31096, Haifa, Israel. 3. Department of Medical Imaging, Rambam Health Care Campus, Haifa, Israel.
Abstract
BACKGROUND: Hypersplenism-related thrombocytopenia (HST) may delay or preclude chemotherapy. Partial splenic embolization (PSE) has been used at our center to overcome prolonged HST. PATIENTS AND METHODS: Between November 2012 and April 2015, 11 PSE procedures were performed in 10 patients; 9 had metastatic colorectal cancer and 1 had widespread pancreatic cancer. PSE was performed by selective catheterization of the splenic artery followed by injection of embolic particles, ranging from 300-700 um, until a 50% reduction in the splenic parenchyma blush was achieved. RESULTS: Splenomegaly was evaluated by splenic index, mean value 970 cm3 (range, 358-2277 cm3), normal mean 120-480 cm3. Mean platelet count immediately prior to PSE was 64.5 K/UL (range, 17-104 K/UL); within 10-14 days following the procedure, it increased to 224 K/UL (range, 83-669 K/UL). Only one patient's count remained less than 100 K/UL 2 weeks after embolization. After the procedure, all patients complained of mild abdominal pain that lasted for a few days; one patient developed post-embolization syndrome. No other significant complications were observed. Mean hospital stay was 2.5 days (range, 2-5 days). Chemotherapy was resumed 7-53 days (mean, 18 days) after the procedure in nine patients. One patient did not receive chemotherapy; he underwent local treatment of liver metastasis. Prolonged thrombocytopenia recurred in four patients, one of whom was successfully retreated by PSE. CONCLUSIONS: PSE can be considered as a treatment option for HST.
BACKGROUND:Hypersplenism-related thrombocytopenia (HST) may delay or preclude chemotherapy. Partial splenic embolization (PSE) has been used at our center to overcome prolonged HST. PATIENTS AND METHODS: Between November 2012 and April 2015, 11 PSE procedures were performed in 10 patients; 9 had metastatic colorectal cancer and 1 had widespread pancreatic cancer. PSE was performed by selective catheterization of the splenic artery followed by injection of embolic particles, ranging from 300-700 um, until a 50% reduction in the splenic parenchyma blush was achieved. RESULTS:Splenomegaly was evaluated by splenic index, mean value 970 cm3 (range, 358-2277 cm3), normal mean 120-480 cm3. Mean platelet count immediately prior to PSE was 64.5 K/UL (range, 17-104 K/UL); within 10-14 days following the procedure, it increased to 224 K/UL (range, 83-669 K/UL). Only one patient's count remained less than 100 K/UL 2 weeks after embolization. After the procedure, all patients complained of mild abdominal pain that lasted for a few days; one patient developed post-embolization syndrome. No other significant complications were observed. Mean hospital stay was 2.5 days (range, 2-5 days). Chemotherapy was resumed 7-53 days (mean, 18 days) after the procedure in nine patients. One patient did not receive chemotherapy; he underwent local treatment of liver metastasis. Prolonged thrombocytopenia recurred in four patients, one of whom was successfully retreated by PSE. CONCLUSIONS: PSE can be considered as a treatment option for HST.
Authors: Ron C Gaba; Jeremy R Katz; Ahmad Parvinian; Steven Reich; Benedictta O Omene; Felix Y Yap; Charles A Owens; M Grace Knuttinen; James T Bui Journal: Diagn Interv Radiol Date: 2012-08-08 Impact factor: 2.630
Authors: H Beji; C De La Fouchardière; F Desseigne; P Thiesse; B Richioud; F Pilleul Journal: Diagn Interv Imaging Date: 2015-02-27 Impact factor: 4.026
Authors: David C Madoff; Alban Denys; Michael J Wallace; Ravi Murthy; Sanjay Gupta; Edmund P Pillsbury; Kamran Ahrar; Bertrand Bessoud; Marshall E Hicks Journal: Radiographics Date: 2005-10 Impact factor: 5.333
Authors: Timo C Meine; Sabine K Maschke; Martha M Kirstein; Elmar Jaeckel; Becker S Lena; Thomas Werncke; Cornelia L A Dewald; Frank K Wacker; Bernhard C Meyer; Jan B Hinrichs Journal: Medicine (Baltimore) Date: 2021-02-19 Impact factor: 1.817